公开(公告)号：US20140017283A1

公开(公告)日：2014-01-16

申请号：US13939969

申请日：2013-07-11

Applicant: Osiris Therapeutics, Inc.

Inventor： Dana Sue Yoo ,  Jin-Qiang Kuang ,  Jaime Paden ,  Scott A. Maxson ,  Alla Danilkovitch ,  Erasmo Lopez ,  Samson Tom

IPC: A61K35/32

CPC classification number: A61L27/3612 ,  A61K35/32 ,  A61K38/014 ,  A61L27/24 ,  A61L27/3608 ,  A61L27/3654 ,  A61L27/3683 ,  A61L27/3687 ,  A61L27/3691 ,  A61L27/3817 ,  A61L27/3852 ,  A61L27/50 ,  A61L27/54 ,  A61L27/56 ,  A61L2300/414 ,  A61L2300/64 ,  A61L2430/06

Abstract: This invention provides porated cartilage products, methods of producing porated cartilage products, and methods of treating subjects by administering cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.

Abstract translation: 本发明提供了开放的软骨产品，生产门软骨产品的方法，以及通过施用软骨制品治疗受试者的方法。 任选地，软骨产品的尺寸，开口和消化以提供柔性软骨产品。 任选地，软骨产品包括活的软骨细胞，生物活性因子如软骨形成因子和II型胶原蛋白。 任选地，软骨产品是非免疫原性的。

公开(公告)号：US20030103951A1

公开(公告)日：2003-06-05

申请号：US10278148

申请日：2002-10-22

Applicant: Osiris Therapeutics, Inc.

Inventor： Mark F. Pittenger ,  Stephen L. Gordon ,  Alastair Morgan Mackay ,  Bradley J. Martin

IPC: A61K048/00

CPC classification number: C12N5/0657 ,  A61K35/12 ,  A61K48/00 ,  A61K2035/124 ,  C12N5/0663 ,  C12N2500/90 ,  C12N2510/02 ,  C12N2533/54

Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

公开(公告)号：WO2017223520A1

公开(公告)日：2017-12-28

申请号：PCT/US2017/039123

申请日：2017-06-23

Applicant: OSIRIS THERAPEUTICS, INC.

Inventor： SINCLAIR, Steven Michael ,  DANILKOVITCH, Alla ,  SATHYAMOORTHY, Malathi ,  KUANG, Jin-Qiang ,  DHALL, Sandeep ,  MELCHIORRI, Anthony John

IPC: A01N1/02 ,  A61F2/10 ,  A61F2/28 ,  A61L27/36 ,  A61L27/38 ,  A61L27/54

Abstract: Disclosed are methods of lyophilizing a tissue sample comprising obtaining a tissue sample, contacting the tissue sample with a lyoprotectant solution, freezing the tissue sample, performing a first drying step of the tissue sample after freezing, and performing a second drying step of the tissue sample after the first drying step. Disclosed are lyophilized tissues prepared using the disclosed methods of lyophilizing a tissue sample comprising obtaining a tissue sample, contacting the tissue sample with a lyoprotectant solution, freezing the tissue sample, performing a first drying step of the tissue sample after freezing, and performing a second drying step of the tissue sample after the first drying step. Disclosed are methods of treating a wound or tissue defect comprising administering a reconstituted lyophilized tissue to the wound or tissue defect.

Abstract translation: 公开了冻干组织样品的方法，包括获得组织样品，使组织样品与冻干保护剂溶液接触，冷冻组织样品，冷冻后进行组织样品的第一干燥步骤， 在第一干燥步骤之后的组织样本的第二干燥步骤。 公开了使用冻干组织样品的公开方法制备的冻干组织，包括获得组织样品，使组织样品与冻干保护剂溶液接触，冷冻组织样品，冷冻后进行组织样品的第一干燥步骤， 在第一干燥步骤之后干燥组织样品的步骤。 公开了治疗伤口或组织缺损的方法，包括将重建的冻干组织施用于伤口或组织缺陷。

公开(公告)号：WO2014011891A1

公开(公告)日：2014-01-16

申请号：PCT/US2013/050094

申请日：2013-07-11

Applicant: OSIRIS THERAPEUTICS, INC.

Inventor： YOO, Dana Sue ,  KUANG, Jin-Qiang ,  PADEN, Jaime ,  MAXSON, Scott A. ,  DANILKOVITCH, Alla ,  LOPEZ, Erasmo ,  TOM, Samson

IPC: A61F2/28

CPC classification number: A61L27/3612 ,  A61K35/32 ,  A61K38/014 ,  A61L27/24 ,  A61L27/3608 ,  A61L27/3654 ,  A61L27/3683 ,  A61L27/3687 ,  A61L27/3691 ,  A61L27/3817 ,  A61L27/3852 ,  A61L27/50 ,  A61L27/54 ,  A61L27/56 ,  A61L2300/414 ,  A61L2300/64 ,  A61L2430/06

Abstract: This invention provides porated cartilage products and methods of producing porated cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.

Abstract translation: 本发明提供了有价软骨产品和生产门软骨产品的方法。 任选地，软骨产品的尺寸，开口和消化以提供柔性软骨产品。 任选地，软骨产品包括活的软骨细胞，生物活性因子如软骨形成因子和II型胶原蛋白。 任选地，软骨产品是非免疫原性的。

公开(公告)号：WO2011103462A1

公开(公告)日：2011-08-25

申请号：PCT/US2011/025478

申请日：2011-02-18

Applicant: OSIRIS THERAPEUTICS, INC. ,  TOM, Samson ,  DANILKOVITCH, Alla ,  YOO, Dana ,  JANSEN, Timothy ,  KUANG, Jin-Qiang ,  MARCONI, Jennifer Michelle

Inventor： TOM, Samson ,  DANILKOVITCH, Alla ,  YOO, Dana ,  JANSEN, Timothy ,  KUANG, Jin-Qiang ,  MARCONI, Jennifer Michelle

IPC: A61K35/50

CPC classification number: A61K35/28 ,  A01N1/0221 ,  A61K35/50 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/39 ,  A61K38/57 ,  C12N5/0605 ,  C12N2500/02 ,  C12N2501/115 ,  C12N2502/025

Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Abstract translation: 本文提供了包含免疫兼容的羊膜的胎盘产品。 这样的胎盘产物可以冷冻保存并且解冻后含有可行的治疗细胞。 本发明的胎盘产品可用于通过将胎盘产品应用于损伤来治疗患有组织损伤（例如伤口或烧伤）的患者。 类似的应用可用于韧带和腱修复以及植入手术如骨移植。

公开(公告)号：WO2011103451A1

公开(公告)日：2011-08-25

申请号：PCT/US2011/025465

申请日：2011-02-18

Applicant: OSIRIS THERAPEUTICS, INC. ,  TOM, Samson ,  DANILKOVITCH, Alla ,  YOO, Dana ,  JANSEN, Timothy ,  KUANG, Jin-Qiang ,  MARCONI, Jennifer Michelle

Inventor： TOM, Samson ,  DANILKOVITCH, Alla ,  YOO, Dana ,  JANSEN, Timothy ,  KUANG, Jin-Qiang ,  MARCONI, Jennifer Michelle

IPC: C12N5/071

CPC classification number: A61K35/28 ,  A01N1/0221 ,  A61K35/50 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/39 ,  A61K38/57 ,  C12N5/0605 ,  C12N2500/02 ,  C12N2501/115 ,  C12N2502/025

Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Abstract translation: 本文提供的是包含免疫兼容性绒毛膜的胎盘产品。 这样的胎盘产物可以冷冻保存并且解冻后含有可行的治疗细胞。 本发明的胎盘产品可用于通过将胎盘产品应用于损伤来治疗患有组织损伤（例如伤口或烧伤）的患者。 类似的应用可用于韧带和腱修复以及植入手术如骨移植。

公开(公告)号：WO0132189A9

公开(公告)日：2002-07-04

申请号：PCT/US0029815

申请日：2000-10-26

Applicant: OSIRIS THERAPEUTICS INC

Inventor： MCINTOSH KEVIN R ,  MOSCA JOSEPH D ,  KLYUSHENKOVA ELENA N

IPC: A61K35/12 ,  A61K35/14 ,  A61K35/28 ,  A61K39/00 ,  A61P37/06 ,  A61P43/00 ,  C12N5/0775 ,  C12N5/0783

CPC classification number: A61K35/28 ,  A61K39/001 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2039/515 ,  A61K2039/5158 ,  C12N5/0636 ,  C12N5/0663 ,  C12N2501/24 ,  C12N2502/1358

Abstract: A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. The mesenchymal stem cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with mesenchymal stem cells.

Abstract translation: 通过用有效减少或抑制移植物的宿主排斥的一定量的间充质干细胞来治疗所述受体而减少受体中移植物的免疫应答的方法。 间充质干细胞可以在移植之前，同时或之后施用。 还公开了通过用间充质干细胞处理诱导针对宿主的外源性组织降低的免疫应答的方法，即移植物抗宿主病。

公开(公告)号：WO0059933A3

公开(公告)日：2001-02-15

申请号：PCT/US0008751

申请日：2000-03-31

Applicant: OSIRIS THERAPEUTICS INC ,  DEN BOS CHRISTIAN VAN ,  MBALAVIELE GABRIEL

Inventor： VAN DEN BOS CHRISTIAN ,  MBALAVIELE GABRIEL

IPC: C12N15/09 ,  C07K14/47 ,  C07K16/18 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/12 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/68

CPC classification number: C07K14/47

Abstract: A human mesenchymal stem cell (hMSC) cDNAs and putative polypeptides derived from Open Reading Frames contained therein are disclosed. Also disclosed are methods for utilizing the polynucleotides and polypeptides, including use as reagents for chromosomal mapping and identification, DNA fingerprinting and the possible role played by genetic mutations in the disease process, and for the generation of polyclonal and/or monoclonal antibodies specific for said polypeptides.

Abstract translation: 公开了一种人间充质干细胞（hMSC）cDNA和衍生自其中所含的开放阅读框架的推定多肽。 还公开了利用多核苷酸和多肽的方法，包括用作染色体作图和鉴定的试剂，DNA指纹图谱，以及在疾病过程中遗传突变所起的可能作用，以及产生对所述多核苷酸和多肽特异的多克隆和/或单克隆抗体 多肽。

公开(公告)号：WO0029002A3

公开(公告)日：2000-10-05

申请号：PCT/US9926927

申请日：1999-11-12

Applicant: OSIRIS THERAPEUTICS INC ,  THIEDE MARK ,  FLAKE ALAN

Inventor： THIEDE MARK ,  FLAKE ALAN

IPC: A61K35/12 ,  A61K48/00 ,  A61L27/00 ,  C12N5/0775 ,  A01K67/027 ,  A61K35/28 ,  C12N5/00 ,  C12N15/00

CPC classification number: A61K35/28 ,  A61K35/12 ,  C12N5/0663

Abstract: The present invention is directed to mesenchymal stem cells for transplantation in utero. Such mesenchymal stem cells may be employed in a method of treating a fetus, or in a method of engrafting mesenchymal stem cells, or in a method of preparing an organ for transplantation.

Abstract translation: 本发明涉及在子宫内移植的间充质干细胞。 这样的间充质干细胞可以用于治疗胎儿的方法，或者在移植间充质干细胞的方法中或在制备移植器官的方法中使用。

公开(公告)号：WO9964565A9

公开(公告)日：2000-04-13

申请号：PCT/US9912847

申请日：1999-06-08

Applicant: OSIRIS THERAPEUTICS INC

Inventor： THIEDE MARK A ,  MBALAVIELE GABRIEL

IPC: A61K35/12 ,  A61K48/00 ,  A61P19/00 ,  C12N5/078 ,  C12N5/06 ,  C12N5/08 ,  C12N5/10

CPC classification number: C12N5/0643 ,  A61K48/00 ,  C12N2500/38 ,  C12N2500/42 ,  C12N2501/39 ,  C12N2502/1358 ,  C12N2503/02 ,  C12N2510/00 ,  C12N2533/18

Abstract: The invention relates to the induction of hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, and, in a preferred embodiment, using no exogenous cytokines. Differentiation of the mesenchymal stem cells into osteoblasts inhibited the differentiation of hematopoietic stem cells into osteoclasts. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate bone resorption.

Abstract translation: 本发明涉及通过用人间充质干细胞培养造血干细胞诱导造血干细胞分化成破骨细胞，并且在优选实施方案中，不使用外源细胞因子。 间充质干细胞向成骨细胞的分化抑制了造血干细胞向破骨细胞的分化。 另外，造血干细胞可以被基因工程改造以携带感兴趣的基因，特别是用于表达生理活性蛋白质。 在间充质干细胞的存在下，转导的细胞携带新的遗传物质并表达可用于调节骨吸收的基因产物。